Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

Inclusion Criteria

• •Singed informed consent.
• •Women with Age ≥ 18 years.
• •1. -In women of childbearing age it should be documented: a) negative pregnancy test in serum at the beginning of the study (14 days before the start of QT-RT); b) Accept the use of some method of contraception approved by your attending physician during the study and 12 weeks after the treatment has ended.
• •2. -In postmenopausal women (surgical or natural menopause) at least one of the following parameters must be met for inclusion.
• •Previous bilateral oophorectomy
• •Age ≥ 60 years
• •Age \<60 years and amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal interval parameters.
• •Diagnosis of CaCu EC IB2 mg/dl With histological confirmation (epidermoid, adenocarcinoma or adenoescamoso).
• •Patients who are candidates for treatment with concomitant QT / RT.
• •ECOG 0-2.
• •Measurable disease by CT scan and magnetic resonance imaging of the pelvis according to the RECIST criteria v1.1
• •No previous treatment.
• •Creatinine clearance ≥ 60 ml / min calculated by the CKD-EPI formula.
• •Patients with adequate hematological and hepatic functioning, defined by the following parameters:
• •1. Hb equal to or greater than 10g /l. (Transfusion prior to treatment is allowed to reach this level of hemoglobin).
• •2. Leukocytes greater than or equal to 4000 / mm3.
• •3. Platelets equal to or greater than 100,000mm3.
• •4. Total bilirubin ≤1.5 times the upper limit of normal (ULN) and. Transaminases less than 1.5 times the LSN
• •Patients with a prior diagnosis of the following comorbidities:
• •* Diabetes mellitus type 2, which has: fasting serum glucose \<250 mg/dl.
• •* Systemic arterial hypertension G1 or G2 according to CTCAE v4.03
• •* Child Pugh A liver disease
• •* Cardiovascular diseases such as: Ischemic heart disease undergoing asymptomatic treatment, without clinical data of stable or unstable angina or for acute myocardial infarction.
• •* Compensated heart failure in functional class I of the New York Heart Association.
• •* Systemic Lupus Erythematosus with mild or inactive lupus activity (less than or equal to 4 points according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).